Taking into account Chinese pharmaceutical procurement policies, the findings highlight the superior efficacy of NOACs, especially rivaroxaban, in enhancing both the quality of life and economic benefits for Chinese LVT patients. NOACs present a more cost-effective treatment option, improving patient quality of life and healthcare cost efficiency compared to warfarin.
Keyphrases
- oral anticoagulants
- atrial fibrillation
- healthcare
- left ventricular
- left atrial
- heart failure
- pulmonary embolism
- venous thromboembolism
- ejection fraction
- direct oral anticoagulants
- end stage renal disease
- newly diagnosed
- public health
- catheter ablation
- prognostic factors
- aortic stenosis
- case report
- percutaneous coronary intervention
- hypertrophic cardiomyopathy
- mitral valve
- acute coronary syndrome
- coronary artery disease
- health information
- patient reported